Clinical trial
DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung…
NCT00298298 · AVAX Technologies, Industry · Terminated
Key facts
| NCT number | NCT00298298 |
|---|---|
| Title | DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer |
| Official title | L-Vax: A Feasibility Study Using a DNP-Modified Autologous Tumor Cell Vaccine as Therapy in Patients With Resectable Non-Small Cell Lung Cancer |
| Lead sponsor | AVAX Technologies, Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer - Completely Resectable |
| Intervention type | Biological |
| Interventions | L-Vax: Autologous, DNP-Modified NSCLC Vaccine |
| Enrollment | 6 |
| Start date | Jan 1, 2006 |
| Primary completion | Jan 1, 2014 |
| Completion | Jan 1, 2014 |
| First posted | Mar 2, 2006 |
| Last update posted | Dec 3, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: